Nephros, Inc. NEPH
Regular-session close
After hours · Nov 19, 7:41 PM ET
- YTD
- -41.80%
- 1 year
- -43.54%
5D +0.01 (+0.33%)
- Market cap
- 30.87M
- Revenue (ttm)
- 13.77M
- Profit margin
- -9.40%
- EPS (ttm)
- 0.17
- Shares out
- 10.54M
- P/E ratio
- 16.71
- Forward P/E
- 148.50
- YTD return
- -41.80%
- 1-year return
- -43.54%
- Volume
- 56.02K
- Avg volume
- 48.94K
- Open
- 2.99
- Previous close
- 2.89
- Day's range
- 2.82 – 2.99
- 52-week range
- 2.78 – 5.79
- Beta
- 1.19
- Price target
- 4.75 (+67.3%)
- 50-day average
- 1.52
Key statistics
- 200-day average
- 1.93
- Enterprise value
- 14.84M
- Price / sales
- 1.14
- Price / book
- 1.87
- Revenue growth
- -8.30%
- Free cash flow
- -235.88K
- Total cash
- 3.08M
- Total debt
- 1.58M
- Return on equity
- -15.61%
- Short % of float
- 0.01%
Fundamental scorecard
14 of 25 checks passed on NEPH’s reported financials
14of 25 checks passed
- Value 3 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | 0.02 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.03 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -0.02 | — | — |
| Mar 7, 2024 | Dec 1, 2023 | 0.00 | -0.06 | — | — |
| Nov 8, 2023 | Sep 1, 2023 | 0.00 | -0.02 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | -0.04 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 12, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| May 15, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Mar 8, 2024 | Benchmark | up | Hold | Speculative Buy |
| Jan 26, 2021 | B. Riley Securities | init | — | Buy |
| Oct 24, 2019 | Benchmark | init | — | Speculative Buy |
| Oct 4, 2019 | Maxim Group | init | — | Buy |
About Nephros, Inc.
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- nephros.com
News
Nephros (NEPH) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
New Strong Buy Stocks for November 12th
Nephros, Inc. (NEPH) Q3 2026 Earnings Call Transcript
Nephros Announces Strong Third Quarter 2026 Financial Results
Nephros Announces Strong Third Quarter 2026 Financial Results Nephros Q3 EPS $0.05 Beats $0.03 Estimate, Sales $5.622M Beat $5.492M Estimate
�Nephros Schedules Third Quarter 2026 Financial Results Conference Call
Nephros Schedules Third Quarter 2026 Financial Results Conference Call
Contrasting Nephros (NASDAQ:NEPH) & Nyxoah (NASDAQ:NYXH)
Nephros Q2 Earnings Call Highlights
Your note
Sign in to keep a note on NEPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMRON ARTHUR H | Director | Purchase | May 29, 2024 | 103,463 |
| BANKS ROBERT R JR. | Chief Executive Officer | Purchase | May 15, 2024 | 70,000 |
| GWYDIR TOM | Director | Stock Award(Grant) | Jan 4, 2023 | 43,226 |
| HARRIS JOSEPH MICHAEL | Director | Stock Award(Grant) | Dec 12, 2023 | 17,693 |
| LASK ALISA | Director | Stock Award(Grant) | Dec 12, 2023 | 48,629 |
| SPANDOW OLIVER J | Director | Stock Award(Grant) | Dec 12, 2023 | 81,604 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Wexford Capital LP | 46.93% | 3,600,552 | 5.35M | Sep 29, 2024 |
| Vanguard Group Inc | 2.63% | 201,994 | 299.96K | Sep 29, 2024 |
| Bard Associates Inc. | 2.25% | 172,371 | 255.97K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.11% | 85,249 | 126.59K | Sep 29, 2024 |
| HighTower Advisors, LLC | 0.75% | 57,210 | 84.96K | Sep 29, 2024 |
| Blair (William) & Company, L.L.C. | 0.47% | 36,249 | 53.83K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.69% | 129,656 | 192.54K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.94% | 72,338 | 107.42K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.72% | 54,913 | 81.55K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.18% | 14,106 | 20.95K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 8,136 | 12.08K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional US Core Equity 1 ETF | 0.07% | 5,000 | 7.42K | Jul 30, 2024 |
